Skip to main content
DFTX $29.12 -0.88%
DFTX logo
DFTX · Definium Therapeutics, Inc.
Track DFTX — free
$29.12 -0.26 (-0.88%) At close · Nov 18 Play latest call Q3 2026 earnings call transcript
Market Cap
$3.99B
Shares
136.90M
Volume · Nov 18 1.92M Avg daily vol (3M) 1.96M
All webcasts

Conference · 2026-11-17

Definium Therapeutics, Inc. (DFTX) November 17, 2026 Conference Transcript

Concluded Nov 17, 2026 Audio replay
Nov 17, 2026 25:08 47 turns
Period
2026-11-17
Runtime
25:08
Sources
2 artifacts

Transcript & audio

25:08 Audio
Andrew Tsai Analyst — Jefferies

Okay, we're going to get started. Welcome to day two of our London Health Care Conference. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies, and it's my pleasure to have Rob Barrow, CEO of Definium. Welcome, Rob.

Thanks so much, Andrew.

Andrew Tsai Analyst — Jefferies

I think a lot of us are familiar with the Definium story, but there might be a few people who are unfamiliar. So would you mind talking about what you're working on, how you are differentiated out there, what catalysts we can expect over the next 6 to 12 months? That would be very helpful.

Yeah, absolutely. So Diffinium is developing our lead program and a few programs in the clinic. Our lead program is a proprietary form, an ODT of LSD. Obviously, the drug has been around for about 80 years, but we've brought it back into the clinic. And over the summer, we had three positive pivotal readouts in generalized anxiety disorder and major depressive disorder. We also just released some preliminary data from our second program, RMDMA and autism spectrum disorder, five patients where we saw a really clear signal and are now advancing that further into the clinic. Part of a broader... Really exciting phase of psychiatry where this is a reinvigoration of a field that hasn't had anything new in a very long time, and GAD especially, there hasn't been a new approval in 20 years almost. And so to bring a drug that we've now seen over those studies, the largest effect in both indications ever in a pivotal study, with a single dose of drug, patients are in the clinic for, on average, about six hours, and then go about their lives, And a big portion of those patients are meaningfully better for a very long time with just one or a few doses. And so this entirely new paradigm is obviously moving into a world of interventional psychiatry that has come into its own in the last several years and had extraordinary excitement for the field. And now with this kind of evidence, we're taking the next step. We're progressing over the next 6-12 months. We'll have, in 2027, a readout from our fourth pivotal study, our second study in major depressive disorder. We will have, we expect it to be filing our NDA in the first half of next year, and we're getting ready to, you know, assuming we get the drug approved, we're ready to go launch this in a really meaningful way.

Andrew Tsai Analyst — Jefferies

Okay, thanks. And so, like you said, two successful GAD data sets, phase three, and then one phase three major depression data set right now. As we think about the market opportunity, can you just remind us in your internal models how many patients you would need to get to a billion in peak sales? What's that pricing bookend look like?

Yeah, obviously, we haven't announced a price of the drug, given where we are, but when we look at analogs out in the world, I mean, intranasal ascetamy is one that, for a lot of reasons, has its limitations as an analog, but in many cases, it's a reasonable thing to look to, and this is J&J's Spravato, and now I'm doing about $2 billion in annual revenues with that product. Pricing range tends to be in the $30,000 to $70,000 range, so midpoint, around $50,000 a year. Obviously, some different dynamics, up to 56 doses a year for that drug versus just a few for ours. When we talk about pricing and think about annual pricing, it's just an analog that is easier to point to that's out in the world for a new branded and interventional psychiatry drug. Obviously, if you use that number, you don't need many patients to get to some really meaningful revenue numbers. And given the market opportunity, there's 50 million patients in the U.S. alone with these two disorders. About half of them are diagnosed, about half of those are treated, and about a third of those have not responded to two or more drugs and would easily make it to a step three therapy. So it's about four million patients, obviously, to get to, again, some really eye-watering numbers of patients that we can hopefully help. Translates into meaningful revenue.

Andrew Tsai Analyst — Jefferies

Great. And so as we look ahead, I noticed you mentioned you're filing an NDA in first half 2027, but you didn't necessarily specify whether it's for GAD or MDD or GAD plus MDD. So I think at one point very recently you've entertained the notion that maybe you could file jointly for both MDD and GAD together based on the three data sets you have. Is that still a possibility, in your view?

We've got a number of options available to us. I mean, our focus, we really think about the end goal here, which is the opportunity to launch a drug, really for the first time that we're aware of, with both generalized anxiety disorder and major depressive disorder on the label. Most of the times, they're staggered by several years. Typically, for the last class of drugs for SRIs, it started with depression and moved into anxiety over time. If successful, we could get in a place where we're launching DT120 for both indications, two of the biggest markets in all of medicine, given the scope of how many people this affects. Filing strategy is something we said we have a pre-MDA meeting in the fourth quarter. Once we have minutes in hand, we'll be able to provide real more granular clarity on that. A few different possibilities there. We obviously have the second MDD study in depression that we'll be reading out in 2027. A few different paths. One would be to file concurrently. The original plan, as we conceived of the program, we had started our GAD program so far in advance of MDD. We were planning initially to file GAD first and file an SMDA with MDD, assuming we get the GAD indication approved. The third possibility is that we stagger the filing. So with a controlled substance, after approval, there's a 90-day window where DEA has to take action, issue, schedule for the drug before it can actually go and be marketed. So there's another path where we could actually stagger the submissions, not submit them together, but also end up in the same situation where we're launching them together. So, any number of those could remain on the table and will provide some additional clarity. It also intersects with the timing of the second MDD data because we want to have that upside opportunity to get those on the label, but also want to present the most compelling data package to FDA and to clinicians, to everyone, so that if we're successful in that, we have the strongest body of evidence to stand behind.

Andrew Tsai Analyst — Jefferies

Okay. And so, the plan is you're talking to the FDA in Q4. We're in the middle of November. Have you spoken to the FDA?

We haven't been talking about it, I think, as we come out with minutes, and one of the things, we have such a great dialogue and such a great relationship with the review division, with psychiatry at FDA. They've been incredibly thoughtful leaders and partners, I think, for the entire field, and certainly for us. We have breakthrough therapy designation for both of these programs. That gives us an opportunity to engage with FDA on a really, nearly ongoing basis, really frequently. And we've taken that opportunity, and they've, again, shown up and been great partners and provided that ongoing feedback. So while we haven't said exactly which meetings we've had when, we have a frequent and ongoing dialogue that constructively moves us in the direction of having a clear path.

Andrew Tsai Analyst — Jefferies

Okay, I understand. And the meeting minutes typically are 30 days from? After meetings, yeah.

Okay.

Andrew Tsai Analyst — Jefferies

I'll be patient. And so, in the meantime, for you to file first half 2027, is it really just predicated on this discussion, or is there anything else internally you need to do, like any preclinical work or something like that?

At this point, we're in a place of compiling data. Obviously, the integrated summaries, all the things you need to do to get a full NDA together takes some time. I mean, we all, we tried to move, we've moved it at a lightning pace from the beginning of this program, which started in January 2022, to having all the pivotal work done. In under five years, it's just really, you know, a testament to the incredible team we have. We're not wasting any time from here, but it takes some time to get a file in front of FDA.

Andrew Tsai Analyst — Jefferies

Okay. And then just a housekeeping question. You mentioned the second phase three data set is ready in 2027. Any granularity on that timing, or when could you be prepared to refine that?

Sadly, unsatisfactory, perhaps, but we're not yet ready to refine that. We will probably result along the same lines as when we talk about filing strategy. Again, those intersect so much. We want to be clear about what we're going to be able to share when and why, of course, and so that'll be the stay tuned, I guess.

Andrew Tsai Analyst — Jefferies

Okay, that's very helpful. Thank you. And so as I think about the label, whether it's for GAD and or MDD, how do you envision the front page label? To read, actually, because, you know, I think when I spoke to Compass, I think it could be, you know, one or two off-front doses, retreat as needed, but is that something you envision, too, for your label?

The way we conceive of this, and we've talked about this with. Number of regulators and stakeholders, as symptoms emerge, so someone presents initially with symptoms, and they would be presumably given a dose of drug, and if they get better, in many cases, we see patients take one dose, get dramatically better, and stay that way for as long as we've followed them, and it's a really exceptional outcome. It's something we hope for everybody. For those who do not get an adequate response, what we've done to characterize retreatment is in the nine-month extension phase of our studies, patients can have an open-label dose of drug up to four times if they have a return of moderate or worse symptoms. That gives us the ability to see what retreatment looks like, to characterize safety, to sort of understand the dynamics in a more real-world-like fashion. And so we would expect there to effectively be that. As symptoms return, monitor patients, and as symptoms return, they'd be eligible for subsequent doses of the drug.

Andrew Tsai Analyst — Jefferies

Yeah, makes sense. And can you speak a little bit, actually, about your open-label extension data so far for both indications? I mean, that's why I find psychedelics in general very valuable, especially for your program. But, you know, how many patients is it looking, how many doses per year is it looking like for the average patient?

Yeah, so what we've seen is, and what we expected really is a number of different response patterns. So, again, some patients just need one dose, and then for as long as we follow them, meaningfully better. What we've seen so far in the day, we've presented this to about a quarter of the people that we've observed, is one dose has long-lasting effect. For some patients, they need a second dose. About a third of patients, from the data we've put out so far, a third of patients have needed a second dose beyond the 25 percent. So we're around half of patients who The richest data we've put out has been through six months, but when we're seeing this response, it tends to be durable, right? Patients who achieve this better, say, how are you going to measure response remission or as we have set the cutoff for treatment as being less than moderate symptom severity, we see this really pronounced effect. Some patients need a third dose. It really seems like in that one to three dose range is where the vast majority of patients are winding up. I see.

Andrew Tsai Analyst — Jefferies

And then when can we get another cut of that open-level data set? I think you mentioned you shared out six months. Can we expect like nine or 12 months next?

We'll certainly be sharing more data in the not-too-distant future. And again, just incremental clarity on what that real-world profile we expect to look like.

Andrew Tsai Analyst — Jefferies

Okay. And then in the meantime, do you... On CMC Manufacturing. Do you need to really prepare for that? How does that work for your compound?

Everyone needs to prepare for it. We administer a single 100-microgram dose of drug, and so you can imagine just how much supply we have accrued just in the batches that we need to file the NVA. So fortunately, given the potency of this molecule, given the treatment interval that we expect, we're already in an incredible position and have more than enough.

Andrew Tsai Analyst — Jefferies

Okay. And then earlier this year, Trump signed that executive order telling the DEA, please go ahead and reschedule. Have you heard anything on that front for your programs? Because technically, DEA could start rescheduling after phase three data.

We've had a number of conversations with HHS and FDA and DEA and are really trying to engage and follow, in the spirit of that executive order, engage everyone in the federal government in the U.S. to try to make this as efficient and move this forward as best we can. Different Different agencies work at different paces and have different... You know, the leadership, and, you know, we've had a lot of engagement across the board. So some of that includes with DEA, and we're going to continue to have those discussions as we move forward. Obviously, there is a process that is already in place. We'd love to see things accelerate, right? We'd love to see... Now we have pivotal data in hand, and we feel very confident that this could offer something meaningfully different for these patients. There's no reason to wait even a single day, because every day we wait, people are really suffering out in the world. So whatever we can do to speed it up, we absolutely will. I know there's a general alignment across the board on that, and we're just going to keep showing up and trying to have those conversations.

Andrew Tsai Analyst — Jefferies

Yeah, and one more on that part is, I think, psychedelics are scheduling right now. I think, for instance, Bravado might be Schedule 3. Is that right? And so if your compound is a Schedule 2, does that matter? Or is it just as long as you're not Schedule 1, the opportunity remains just as attractive?

I think the opportunity is extraordinarily attractive. There have been many Schedule 2 drugs and psychiatry that have been extraordinarily successful. Are there administrative things that you have to do? Of course, right? There are little nuances or things we'll be prepared for. That's what we're going to have to make sure we go out and get the world ready for. At the end of the day, there is such extraordinary need and such incredible enthusiasm from psychiatry to get this done that whatever little wrinkles need ironing out, we feel very confident in the path forward no matter what.

Andrew Tsai Analyst — Jefferies

And by the time you launch your psychedelic, potentially, year-end of next year or early 2028, somewhere around that lens, Compass will have been in the market maybe a year. There's also Spravato. How are you planning to leverage both of their infrastructures or Spravato's infrastructure?

I think the, if you take a step back, the thing that really has happened is that psychiatrists have gotten new tools that they haven't had in a very, very long time. And we tend to shorthand talk about these things as, you know, drug clinics, ketamine clinics, or esketamine clinics, and it's not really what it is, right? These are clinics who offer a number of interventions. Some of them, Spravato, ketamine, TMS, a whole variety of treatment options, med management, talk therapy. There's a whole toolbox for psychiatrists to treat patients, and most of these sites offer a pretty wide combination of those. A thing that is great to see is that they can integrate and they're dynamic and can integrate new practice modalities. We're going to look at the world that exists today, but 10 years None of this was happening. Right? Just dipping the toe in the water with ketamine at that point in time at some of these sites. And so when we know who they are, which we do, and we know what the behaviors are likely to be, which we believe we do, it gives us a great ability to focus on the right providers who have the patients who know how to do this and who are motivated to do so. We know that today. We're obviously going to be watching what everyone does, but we think we have a great understanding of this market And, you know, great tailwinds because of all that's happened now and that will happen over the next couple of years.

Andrew Tsai Analyst — Jefferies

And how should I think about your potential REMS? I think, do you have, what's your base case? Is there an upside scenario? I think my understanding with Spravato's REMS is a healthcare provider must be there. How are you envisioning your REMS?

I think that as a reference point is a great one. We generally think of it structurally in the same way. Obviously, each drug has a little bit of different dynamics in terms of how long patients may need to be monitored and exactly what they're being monitored for. There's some hemodynamic changes with ketamine and esketamine that have pushed it in a particular direction. Obviously, we're going to have to wait for all the drugs in the category to have their evidence in front of FDA before we know exactly what that looks like. Fundamentally, I mean, we have gone to great lengths in our program to document what's happening for patients in the room, right? And I didn't cover it up front, but patients take a single dose of drug, they're monitored, someone's there to make sure that they have what they need and that they're safe. That's all there is effectively to it. If they need reassurance of something, you know, they feel uncomfortable, there's someone there to do that. Proximity to person, the number of people. These are things that reside in the practice of medicine. It's not something that goes on drug labels. There's infinite precedence for that. We have volatile anesthetics that don't prescribe where an anesthesiologist needs to be. That would be kind of wild if that were to be the case. And so with the frameworks that already exist for patient care out in the world, we think there's already a container. And really what are REMS and what we try to document in the development program are the minimum conditions that have to be true for the safe and effective use of a drug. And we're really focused on safety. And so, we now have seen that with esketamine. We've seen a lot of papers written as well about the potential impact on access that an overly burdensome REMS can carry and the reality that these things can be done. We've now had over 1,000 treatment sessions where we've characterized what interventions had to happen, which turns out very, very few. And we've characterized who's in the room, who's doing what during those hours. That esketamine framework is very much applicable here, we think.

Andrew Tsai Analyst — Jefferies

I see. And can you remind me in your clinical studies, was it one or two people inside the room at all times? The real question is, is there a risk? The FDA is going to be like, no, we want the REMS to mimic how your clinical studies were done. Unless maybe Cervato, their REMS was, or sorry, their clinical studies was also people in the rooms at all times.

We put a patient in a room and had one person in the room with them. There was someone else on the site who was watching my video, typically, to make sure, you know, everything's good, but in, I believe, 100% of cases, there was a single person in the room with a patient.

Andrew Tsai Analyst — Jefferies

I see. And who exactly are these, do you envision, at these centers, the people monitoring? Is it a medical doctor, in your view, or could it be someone lower, just another?

In our trials, the vast majority were licensed clinical social workers. These are folks who are giving mental health care today in the U.S. The predominant workforce is providing psychotherapy. They're, you know, widely engaged in being health care providers for psychiatric patients. And so they're also very much connected. A lot of these centers, if you, you know, invite anyone to go on a website of one of these centers and look at who they staff. A lot of times there's a psychiatrist, there's almost always a set of lower degree individuals who are providing care in some other way, and LICSW is very well equipped with the training and the skill set and licensure to do this. And so what we see in the trials, I think there's broad applicability. Our goal in development has been to maximize flexibility for adoption, right? We don't know how to tell every practice in the United States how best to practice for for their patients, for their organization. So we want to set the minimum standards and then go engage with these sites and make sure they have what they need and then we can help them provide the best care based on what their patients need and based on what they're set up to do.

Andrew Tsai Analyst — Jefferies

I see. And in your clinical studies, you know, most of the discharge times were in a range between five to eight hours. What dictates hour five versus getting out hour eight? Where do you think that shakes out in the real world For your compound.

Yeah. What we've seen over time is really a convergence around what the mean was, which was about six hours before people were determined to be safe to go home. We had a structured instrument that we used in the trials to assess this, and so we have, over that range, five to eight hours, hour-by-hour assessments on every item that we're assessing, and this incredibly rich data set to now know exactly why people need to be under observation and for how long. So we just continue to see it, again, sort of converge to around six hours on average.

Andrew Tsai Analyst — Jefferies

I see. And then the CP3 code currently that's available for psychedelics, can you... What's your understanding? How much does that code cover for in terms of the number of hours? Should the psychedelics be approved?

Yeah. Again, so taking a step back, what we're really talking about when we're talking about CPT codes is how they're going to document and how they're going to get paid for time spent watching a patient. And these sites for esketamine today are using CPT1 codes, typically a one-hour code supplemented by four 15-minute codes. You add that up, it's two hours, matches the observation time. Obviously, for six hours, it's different because it's a lot more 15 hours to get to six versus two. Over the course of a year, though, we're talking about what the maximum frequency for esketamine is 56 doses a year. For us, we're talking, again, centering around one to three doses for most patients. Well, three times six versus 56 times two actually turns out to be about an 80-90% reduction. From a value standpoint, there's a number of mechanisms that can be arrived at. CPT-1 codes exist today, sites know what they're going to get paid for them, so that may be the reliable starting place. CPT-3 codes that others have worked on could also be quite... And we have a lot more to be worked out there. There's actually multiple CBT3 codes, some of which are there to accommodate the second monitor, which is more applicable to other drugs. Since there's a lot of wrinkles to be ironed out, at the end of the day, we see a really strong value proposition for why sites should be paid for their time to watch patients, whatever numbers they put down to get paid for them.

Andrew Tsai Analyst — Jefferies

Okay, thanks. And then one curveball in the industry recently was this nonprofit, USONA, filing their, you know, psilocybin compound recently. I guess, you know, investors worry, what if they launched with a low price? Does that set a bad precedent or a negative precedent for, you know, sponsors like you, for instance? What do you say to that, and why do you think your compound is protected and totally fine at the end of the day?

The simple answer is no. Fundamentally, we see extraordinary value in the drug. We're going to engage for patients and for providers in the best way we possibly can. That takes resources, and it takes the ability to go out and build an organization to do this responsibly. We're not marketing psilocybin. We chose our programs and our indications very intentionally for very good reasons, and we're very happy, whatever unfolds with whatever organization, to go out and do this the right way.

Andrew Tsai Analyst — Jefferies

Okay, great. And then you mentioned in the last minute you have a second asset for RMDMA, so the right isomer. Is it the right isomer?

Rectus, yeah.

Andrew Tsai Analyst — Jefferies

Okay, and so you saw a signal in five patients. When do you start phase two, and what are you exactly looking for?

Yeah, Beth. I mean, so we did a study. It was open label. It was up to 20 patients. In the first five, we saw exactly what we needed to see to move forward. Now we're in a stage. I mentioned the sort of sprint pace we've been going on on our lead program, 120. For 402, it's a very different framework. There's a lot of work to be done to optimize dose and regimen. And we've not conceived of this as a single intervention with some long-lasting clinical benefit, but rather more like a psychostimulant model in ADHD. And so a lot of work to be done to, again, optimize dose and regimen and start to see hopefully sustained benefit in these patients over time. So more work ahead of us to get there and be able to provide a little more clarity as we progress.

Andrew Tsai Analyst — Jefferies

Okay. So that's all the time we had. But, Rob, thank you for the updates today, and congrats on all the execution progress so far. Thanks, everyone, for listening.

Analyst Q&A · 1 question
Full-screen source Call document